Clinical trials: Neoplasms, Neuroepithelial
Astrocytoma
SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)
The primary purpose of the study is to evaluate the efficacy (overall response) and safety of temozolomide in Step 1 at the dose and regimen approved in the US and the EU countries (28 day cycles of temozolomide at 150 to 200…
- Trial name
- NCT00783393
- Testing
- Temozolomide
- Volunteers
- 32 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioma
A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma
To determine the safety and efficacy of surgical resection with Gliadel® 3.85% wafer implantation, followed by concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide and bevacizumab in…
- Trial name
- KARE004 (NCT00660621)
- Testing
- Temozolomide and Bevacizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Kentuckiana Cancer Institute
High-grade Glioma, Medulloblastoma
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade…
- Conditions
- High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- AflacBT2303 (NCT06624371)
- Testing
- Atovaquone, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Glioblastoma
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.
- Trial name
- NCT03776071
- Testing
- Enzastaurin Hydrochloride, Temozolomide, Radiotherapy
- Where
- 65 sites in United States, Canada and 1 more
- Volunteers
- 260 people
- Sponsor
- Denovo Biopharma LLC
Amblyopia, Myopia
Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population
Screening of haitian children between the ages of 3 and 6 years old for amblyogenic risk factors with the use of the Spot photoscreener. The photoscreener results will be compared to the complete ophthalmologic evaluation.
- Conditions
- Amblyopia, Myopia, Hyperopia, Astigmatism
- Trial name
- POPH (NCT02655432)
- Testing
- Spot photoscreener, Ophthalmologic evaluation, Cyclopleged refraction
- Where
- 3 sites in Haiti
- Volunteers
- healthy volunteers welcome
- Sponsor
- Université de Montréal
Glioblastoma
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to…
- Trial name
- EF-41 (NCT06556563)
- Testing
- Optune® device, Temozolomide, Pembrolizumab
- Where
- 102 sites in United States, Canada and 10 more
- Volunteers
- 741 people
- Sponsor
- NovoCure GmbH
Glioblastoma, Organoid
Drug Response Testing and Repurposing Using Glioblastoma Organoid
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including…
- Trial name
- NCT06782984
- Testing
- Organoid-based drug sensitivity test
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Chungnam National University Hospital
Glioblastoma Multiforme of Brain
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
In the first phase of this study (Cohort 1), the investigators will determine the feasibility of adding MRSI to the evaluation of newly-diagnosed GBM patients treated with standard RT/TMZ and determine whether magnetic resonance…
- Trial name
- NCT02137759
- Testing
- Standard Radiation Therapy, Standard Temozolomide, Belinostat
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Adult Glioblastoma Multiforme
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Monoclonal antibodies, such as ramucirumab and anti-PDGFR alpha monoclonal antibody IMC-3G3 (Olaratumab), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00895180
- Testing
- olaratumab, ramucirumab
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neuroblastoma
Oral Liquid 13-cis-retinoic Acid (13-CRA)
An open label, randomised, multiple dose, cross-over relative bioavailability and pharmacokinetics trial of a novel oral liquid and capsule formulations of 13-CRA administered to patients from 0 months - < 21 years.
- Trial name
- My-CRA (NCT03291080)
- Testing
- Liquid 13-Cis Retinoic Acid, Extracted capsules 13-CRA
- Where
- 10 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Nova Laboratories Limited
Glioma
Advanced Development of Desorption Electrospray Ionization Mass Spectrometry for Intraoperative Molecular Diagnosis of Brain Cancer Using Pathology Biopsies
This study explores whether DESI-MS can be used to identify cancerous vs. noncancerous tissue during brain tumor surgery.
- Trial name
- NCT06387979
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 285 people
- Sponsor
- Mayo Clinic
Oncology
A Patient-Centric Platform Trial for Precision Oncology
XCELSIOR is a non-interventional data registry. Information about treatments, treatment decisions and rationale, and patient outcomes including safety and effectiveness of anti-cancer therapy and associated supportive care will…
- Trial name
- XCELSIOR (NCT03793088)
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- xCures
Glioblastoma
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
This 2 arm study investigated the efficacy and safety of the addition of bevacizumab to the current standard of care (multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide) as…
- Trial name
- NCT00943826
- Testing
- Bevacizumab, Temozolomide, Radiation therapy
- Where
- 133 sites in United States, Australia and 22 more
- Volunteers
- 921 people
- Sponsor
- Hoffmann-La Roche
Recurrent Glioblastoma Multiforme
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Colloidal Dispersion (NCD) administered in patients…
- Trial name
- NCT00306618
- Testing
- Panzem Nanocrystal Colloidal Dispersion
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- CASI pharmaceuticals, Inc.
Brain and Central Nervous System Tumors, Lymphoma
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT01273090
- Testing
- imetelstat sodium, laboratory biomarker analysis, pharmacological study
- Where
- 23 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
Neuroblastoma is a malignant tumor of the sympathetic nervous system. It is the second most common malignant tumor of childhood.
- Trial name
- NCT00670410
- Testing
- Related donor transplant, Cord blood transplant, Busulfan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Glioma
Fluorescence-guided Surgery for Low- and High-grade Gliomas
Gliomas are the most common primary brain tumor, yet remain a challenge to effectively treat. Mounting evidence suggests that survival improves with greater tumor removal, yet being able do a complete removal can be difficult due…
- Trial name
- BALANCE (NCT01502280)
- Testing
- 5-Aminolevulinic acid (ALA)
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Malignant Brain Tumors, Glioma
Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG
Participants in this research study are people who are likely to have, or have been diagnosed with a brain tumor, for which surgical removal (or "resection") is the standard of care treatment.
- Trial name
- NCT07438860
- Testing
- SBK2-ICG, Craniotomy (Standard of Care)
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Tiffany Hodges
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
RATIONALE: Donepezil may decrease the side effects caused by radiation therapy to the brain. PURPOSE: This clinical trial is studying how well donepezil works in treating young patients with primary brain tumors previously…
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity
- Trial name
- NCT00452868
- Testing
- Donepezil
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Glioma
Awake Intraoperative Language Mapping and Chinese Probabilistic Map Construction
The study aims at constructing a Chinese language probabilistic map by awake intraoperative direct electrical stimulation (DES) language mapping.
- Trial name
- NCT03641391
- Testing
- Intraoperative direct cortical electrical stimulation, Intraoperative direct subcortical electrical stimulation
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Huashan Hospital